Pharmacological therapies for Angelman syndrome; [Pharmakologische Therapien bei Angelman-Syndrom]

被引：9
作者：
Tan W.-H. [1 ]
Bird L.M. [3 ,4 ]
机构：
[1] Harvard Medical School, Boston, MA
[2] Department of Pediatrics, University of California, San Diego, CA
[3] Division of Genetics/Dysmorphology, Rady Children’s Hospital San Diego, 3020 Children’s Way, # 5031, San Diego, 92123, CA
来源：
Wiener Medizinische Wochenschrift | 2017年 / 167卷 / 9-10期
关键词：
Angelman syndrome; Clinical trial; Mouse model; Therapeutic; Therapy;
D O I：
10.1007/s10354-015-0408-z
中图分类号：
学科分类号：
摘要：
Angelman syndrome (AS) is a severe neurodevelopmental disorder caused by a loss of the maternally inherited UBE3A; the paternal UBE3A is silenced in neurons by a mechanism involving an antisense transcript (UBE3A-AS). We reviewed the published information on clinical trials that have been completed as well as the publicly available information on ongoing trials of therapies for AS. Attempts at hypermethylating the maternal locus through dietary compounds were ineffective. The results of a clinical trial using minocycline as a matrix metalloproteinase-9 inhibitor were inconclusive; another clinical trial is underway. Findings from a clinical trial using L-dopa to alter phosphorylation of calcium/calmodulin-dependent kinase II are awaited. Topoisomerase inhibitors and antisense oligonucleotides are being developed to directly inhibit UBE3A-AS. Other strategies targeting specific pathways are briefly discussed. We also reviewed the medications that are currently used to treat seizures and sleep disturbances, which are two of the more debilitating manifestations of AS. © 2015, Springer-Verlag Wien.
引用
收藏
页码：205 / 218
页数：13
相关论文
共 117 条
[21]  
Bird L.M., Tan W.H., Bacino C.A., Et al., A therapeutic trial of pro-methylation dietary supplements in Angelman syndrome, Am J Med Genet A, 155 A, pp. 2956-2963, (2011)
[22]  
Huang H.S., Allen J.A., Mabb A.M., Et al., Topoisomerase inhibitors unsilence the dormant allele of Ube3a in neurons, Nature, 481, pp. 185-189, (2012)
[23]  
Powell W.T., Coulson R.L., Gonzales M.L., Et al., R-loop formation at Snord116 mediates topotecan inhibition of Ube3a-antisense and allele-specific chromatin decondensation, Proc Natl Acad Sci U S A, 110, pp. 13938-13943, (2013)
[24]  
Skourti-Stathaki K., Proudfoot N.J., A double-edged sword: r loops as threats to genome integrity and powerful regulators of gene expression, Genes Dev, 28, pp. 1384-1396, (2014)
[25]  
King I.F., Yandava C.N., Mabb A.M., Et al., Topoisomerases facilitate transcription of long genes linked to autism, Nature, 501, pp. 58-62, (2013)
[26]  
Plasschaert R.N., Bartolomei M.S., Autism: a long genetic explanation, Nature, 501, pp. 36-37, (2013)
[27]  
Meng L., Person R.E., Huang W., Et al., Truncation of Ube3a-ATS unsilences paternal Ube3a and ameliorates behavioral defects in the Angelman syndrome mouse model, PLoS Genet, 9, (2013)
[28]  
Santos R.D., Raal F.J., Catapano A.L., Et al., Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials, Arterioscler Thromb Vasc Biol, 35, pp. 689-699, (2015)
[29]  
Marafini I., Di Fusco D., Calabrese E., Et al., Antisense approach to inflammatory bowel disease: prospects and challenges, Drugs, 75, pp. 723-730, (2015)
[30]  
Voit T., Topaloglu H., Straub V., Et al., Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study, Lancet Neurol, 13, pp. 987-996, (2014)
12345678910